Introduction
Familial Mediterranean fever (FMF) is an autosomal recessive disorder (MIM# 249100) characterised by multiple attacks of serosal inflammation. It affects primarily people of Mediterranean extraction, mostly Sephadic Jews, Armenians, Arabs and Turks. 1, 2 It is very common in the populations at risk with estimated carrier rates of 1/6 in Armenians, 1/7 in North African Jews and 1/13 in Iraqi Jews. 3, 4 The gene causing FMF (MEFV) has been cloned and five common founder mutations (M694V, V726A, M680I, M694I, E148Q), each segregating with one ancestral haplotype, were identified.
5 ± 8 SNP haplotype data, recently presented, is consistent with the opinion that each of these mutations share a common progenitor. 8 To better define the distribution and penetrance of MEFV mutations in our heterogeneous population consisting of Jews and Arabs we tested 146 unrelated FMF patients and compared the frequencies and distribution of these mutations in our patients to that observed in 1173 individuals, of pertinent ethnic groups, unselected for personal or family history of FMF. attended our Rheumatology clinic between 1998 and 2000, and 1173 healthy individuals who presented for heterozygote detection of recessive diseases (cystic fibrosis and other). Patients' group included 75 Jewish (50 North African, three Ashkenazi, 12 non-Ashkenazi, 10 of mixed Jewish descent) and 71 Arab (56 Muslim, 10 Christian, five Druze) individuals. The healthy population included individuals who previously signed a consent form allowing the use of their DNA for research purposes and for whom DNA was available. It was composed of Ashkenazi (n=407), Iraqi (n=205) and Moroccan Jews (243) and 318 Muslim Arabs. The study had the approval of the Ethical Committee at Rambam Medical Center. Patients' blood samples were systematically screened for the five founder mutations (M680I, M694V, M694I, V726A, E148Q). When patients of mixed Jewish origin were found to carry two different mutations, we analysed one of the two parents in order to determine the exact origin of the mutations. The healthy control population was differentially screened for the four most common mutations (M694V, M680I, V726A and E148Q). We did not screen the healthy population for mutation M694I, which is rather rare and preferentially distributed among our patients of Druze and Christian Arab origin (data not shown).
Mutation analysis
Mutations V726A and E148Q create a constitutive restriction site. They were distinguished by PCR amplification followed by digestion with appropriate enzymes made to distinguish the wild type allele from the mutant allele, as previously described. 8, 10 Mutation M680I (either a or b) abolishes a constitutive restriction site. PCR amplification followed by digestion with Hinf-I distinguishes the wild type allele from the mutant allele. 8, 10 Mutations M694V and M694I were detected by PCR amplification with specific primers that produce a modified restriction enzyme digest made to distinguish the wild type allele from the mutant allele, as previously described. 10 
Statistical analysis
The proportion of individuals positive for the mutated alleles was calculated for each ethnic subgroup (Ashkenazi, Iraqi and Moroccan Jews and Moslem Arabs) and a 95% CI, based on the binomial distribution, was determined. In nine individuals who carried more than one mutation, each mutation was counted separately.
Results

Distribution of founder mutations in FMF patients
Ninety-one per cent of mutation bearing chromosomes from 146 unrelated Jewish (n=75) and Arab (n=71) patients were characterised ( Frequency and distribution of founder mutations in the general population (Table 2 ) One hundred and ninety-one mutated alleles were identified in 181 individuals, nine of whom had two mutated alleles (three compound M694V/V726A heterozygotes; two V726A homozygotes; one M680I homozygote; one compound M680I/V726A heterozygote; one compound E148Q/V726A heterozygote; one compound E148Q/M694V heterozygote).
FMF carrier frequencies were extremely high in all populations studied. The frequency of mutation M694V was highest in Moroccan Jews ± 0.55 (95% CI=0.37 ± 0.8). It was prevalent among Iraqi Jews ± 0.15 (95% CI=0.05 ± 0.32), rare among Muslim Arabs ± 0.03 (95% CI=0.004 ± 0.11) and absent from 814 Ashkenazi chromosomes tested. The frequency of mutation V726A was high in Iraqi Jews ± 0.75 (95% CI=0.50 ± 0.11), Ashkenazi Jews ± 0.37 (95% CI=0.25 ± 0.53) and Muslim Arabs ± 0.38 (95% CI=0.25 ± 0.56); It was not found among Moroccan Jews. The frequency of mutation M680I in Muslim Arabs was ± 0.13 (95% CI=0.05 ± 0.25). It was not observed in the Jewish population. Mutation E148Q was ubiquitous and common in all ethnic groups studied, with frequencies of ± 0.55 (95% CI=0.28 ± 0.96) in Moroccan Jews; ± 0.7 (95% CI=0.39 ± 1.15) in Iraqi Jews; ± 0.75 (95% CI=0.5 ± 1.07) in Ashkenazi Jews and ± 0.65 (95% CI=0.35 ± 1.1) in Muslim Arabs.
Discussion
FMF follows an autosomal recessive pattern of inheritance, yet a significant proportion of patients have no known affected relatives. Estimated carrier rates vary from 1/6 ± 1/7 in North African Jews, 1/13 in Iraqi Jews to 1/135 in Ashkenazi Jews. 3, 4, 11 It has been repeatedly shown, that the variable disease phenotype, severe in North African Jews, milder in Iraqi Jews and Druzes is at least partly due to allelic heterogeneity with mutation M694V being associated with a severe phenotype and amyloidosis, and mutation V726A with a milder form of the disease.
± 14
The five common founder mutations are differentially distributed among our patients: M694V, predominant among North African Jews, was detected in all patients other than Ashkenazi Jews; V726A was observed in all patients other European Journal of Human Genetics FMF: Prevalence, penetrance and genetic drift R Gershoni-Baruch et althan North African Jews; M680I is common and confined to Arab patients; M694I is rare and confined to Arab patients; E148Q is occasionally encountered in patients from all ethnic groups.
Our population based study shows that the overall carrier frequencies, of the mutations tested, are extremely high in all ethnic groups studied. Three mutations taken together (M694V, M680I, V726A) were observed at rates that vary from 1 : 6 in Iraqi Jews, 1 : 9 in Moroccan Jews, 1 : 13 in Ashkenazi Jews and 1 : 10 in Arabs. The carrier rate of mutation E148Q ranged from 10 to 13% in all populations studied, thereby exceeding that calculated for all other mutations taken together. In patients, however, the E148Q mutation, accounted for only 8.9% of mutated alleles, in line with the opinion that considers this mutation to be of reduced penetrance. 7 Overall carrier rates for the four most common FMF alleles reached 1 : 3.5 in Iraqi Jews, 1 : 4.7 in Moroccan Jews, 1 : 4.5 in Ashkenazi Jews and 1 : 4.3 in Arabs. These rates do not take into account other, rare, mutations recently described.
± 9
The prevalence of mutation V726A, among Ashkenzim, by far exceeds that calculated by disease prevalence, indicating that the bulk of Ashkenazi individuals who comply with the genetic diagnosis of FMF remain asymptomatic or undiagnosed. Among our patients of non-Ashkenazi or Arab origin the V726A allele was detected at rates five times lower than expected based on our calculated carrier frequencies. The high disease prevalence of FMF in non-Ashkenazi Jews should be mainly attributed to mutation M694V known to be associated with a severe phenotype. Although, differences in lifetime cumulative penetrance are by now attributed to different mutations, the V727A mutation remains practically totally silent and non-penetrant in Ashkenazi Jews. Whether this is due to modifier genes or environmental factors remains to be established. 
